In the present study, we sought to investigate the efficacy of BKI-1748 against congenital toxoplasmosis in sheep when the compound is administered from day 7 p.i. onward (at the time of fever peak and increased serum IFNγ levels), which may help to accurately estimate its efficacy in treating real-life acute congenital toxoplasmosis both in animals and humans. Here, IFNG is linked to congenital toxoplasmosis.